Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

Overview of attention for article published in Frontiers in oncology, November 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,681 followers.

RT @FrontOncology: New research: Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhi…

21 Nov 2023

Reply Repost Favourite

New research: Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck: Background Immune checkpoint inhibitors… https://t.co/DC

21 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.